Oral solids · Contract manufacturing in India

B-Carotene 38 mg, Biotin 10 mcg, Cholecalciferol 200 IU, Chromium 10 mcg, Cyanocobalamin 1 mcg, Inositol 10 mg, Iodine 50 mcg, Lysine Hcl 30 mg, Manganese 0.8 mg, Molybdenum 8 mcg, Niacinamide 15 mg, Pyridoxine 1 mg, Selenium 10 mcg, Zinc 3 mg Tablets

Request manufacturing feasibility

Discuss third-party manufacturing of B-Carotene 38 mg, Biotin 10 mcg, Cholecalciferol 200 IU, Chromium 10 mcg, Cyanocobalamin 1 mcg, Inositol 10 mg, Iodine 50 mcg, Lysine Hcl 30 mg, Manganese 0.8 mg, Molybdenum 8 mcg, Niacinamide 15 mg, Pyridoxine 1 mg, Selenium 10 mcg, Zinc 3 mg Tablets with Walter Healthcare, India. Share your target market, required tablet count and finished-pack count, packaging and launch timeline for a product-specific quotation.

Catalogue reference
WH-2920
Composition and strength
B-Carotene 38 mg, Biotin 10 mcg, Cholecalciferol 200 IU, Chromium 10 mcg, Cyanocobalamin 1 mcg, Inositol 10 mg, Iodine 50 mcg, Lysine Hcl 30 mg, Manganese 0.8 mg, Molybdenum 8 mcg, Niacinamide 15 mg, Pyridoxine 1 mg, Selenium 10 mcg, Zinc 3 mg
Dosage form
Tablets
Indicative administration route
Oral
Therapeutic navigation area
Nutrition & supportive care
Pharmacological class
Vitamin D / vitamin D analogue + Amino acid / metabolic nutritional supplement + Vitamin / mineral supplement + Mineral supplement
Manufacturing stream
Non-beta-lactam

Catalogue details support an initial B2B discussion. Walter confirms the applicable unit, current licence scope, formula, target market and commercial feasibility before making a commitment.

Clinical reference

Mechanism and pharmacokinetics.

Explore the published evidence for the ingredients in B-Carotene 38 mg, Biotin 10 mcg, Cholecalciferol 200 IU, Chromium 10 mcg, Cyanocobalamin 1 mcg, Inositol 10 mg, Iodine 50 mcg, Lysine Hcl 30 mg, Manganese 0.8 mg, Molybdenum 8 mcg, Niacinamide 15 mg, Pyridoxine 1 mg, Selenium 10 mcg, Zinc 3 mg Tablets. Each reference identifies its source formulation and study context. Ingredient studies describe the named reference product; they do not establish the pharmacokinetics, clinical suitability or bioequivalence of this finished formulation.

How to read our product information and sources ↗

Additional ingredient references still to be verified: B-Carotene; Inositol; Lysine Hcl; Molybdenum. The references below cover only the named ingredients.

Nutrient reference

Vitamin B12

Reference for: Cyanocobalamin. Source presentation: oral nutrient reference. Source route: oral.

Biological role

Vitamin B12 supplies cofactors for methionine synthase and methylmalonyl-CoA mutase. These reactions support methionine formation and conversion of methylmalonyl-CoA to succinyl-CoA. B12 is involved in DNA synthesis, red-cell formation and nervous-system function.

Absorption and disposition

Free B12 combines with intrinsic factor and is taken up in the distal ileum. Absorption becomes less efficient as the dose exceeds intrinsic-factor capacity; the NIH review reports about 2% absorption at 500 micrograms and 1.3% at 1,000 micrograms. Cyanocobalamin and hydroxocobalamin are converted into active cobalamin forms. These are oral nutrient data, not injectable-product pharmacokinetics.

Nutrient-level summary from NIH. Absorption and disposition describe general oral nutritional physiology, not a pharmacokinetic or bioequivalence study of this finished product.

Source: NIH Office of Dietary Supplements: Vitamin B12

Reference accessed .

Nutrient reference

Vitamin B6

Reference for: Pyridoxine. Source presentation: oral nutrient reference. Source route: oral.

Biological role

Pyridoxal phosphate and pyridoxamine phosphate are active vitamin B6 coenzymes involved in amino-acid metabolism. B6 also contributes to neurotransmitter synthesis, glycogen metabolism and hemoglobin formation.

Absorption and disposition

Vitamin B6 is absorbed in the jejunum. Phosphorylated forms are dephosphorylated before free B6 enters by passive diffusion. The NIH review describes similar absorption from foods and supplements; much of a large pharmacological dose is rapidly eliminated in urine. This physiology does not supply a measured half-life for this formulation.

Nutrient-level summary from NIH. Absorption and disposition describe general oral nutritional physiology, not a pharmacokinetic or bioequivalence study of this finished product.

Source: NIH Office of Dietary Supplements: Vitamin B6

Reference accessed .

Nutrient reference

Vitamin D

Reference for: Cholecalciferol. Source presentation: oral nutrient reference. Source route: oral.

Biological role

Vitamin D is converted to active metabolites that support calcium absorption and mineral homeostasis. The physiological role described by NIH includes maintaining bone mineralization; nutrient physiology alone does not establish a treatment claim for a particular supplement.

Absorption and disposition

Vitamin D2 and D3 are absorbed in the small intestine by passive and carrier-mediated processes. Dietary fat enhances absorption, although absorption also occurs without fat. Liver hydroxylation produces 25-hydroxyvitamin D, followed primarily in the kidney by conversion to calcitriol. These steps describe the precursors, not the pharmacokinetics of administered calcitriol.

Nutrient-level summary from NIH. Absorption and disposition describe general oral nutritional physiology, not a pharmacokinetic or bioequivalence study of this finished product.

Source: NIH Office of Dietary Supplements: Vitamin D

Reference accessed .

Nutrient reference

Zinc

Reference for: Zinc. Source presentation: oral nutrient reference. Source route: oral.

Biological role

Zinc participates in the catalytic activity of numerous enzymes and contributes to protein and DNA synthesis, cell signaling, cell division and normal immune function.

Absorption and disposition

Zinc balance depends on intestinal absorption, secretion into the gastrointestinal tract and reabsorption. Fractional absorption falls as intake rises. Much of the body zinc pool is in muscle and bone. This nutrient-level reference does not establish the absorption rate or bioavailability of a particular zinc salt or combination.

Nutrient-level summary from NIH. Absorption and disposition describe general oral nutritional physiology, not a pharmacokinetic or bioequivalence study of this finished product.

Source: NIH Office of Dietary Supplements: Zinc

Reference accessed .

Nutrient reference

Niacin and nicotinamide

Reference for: Niacinamide. Source presentation: oral nutrient reference. Source route: oral.

Biological role

Niacin supplies precursors for NAD and NADP. These coenzymes participate in cellular oxidation-reduction reactions, energy metabolism and biosynthetic processes. This nutrient role should not be confused with evidence for a lipid-lowering effect of every niacin form.

Absorption and disposition

Ingested niacin is absorbed mainly in the small intestine, with some stomach absorption. Tissues convert physiological amounts to NAD. Excess is metabolized in the liver to methylated and oxidized products that are eliminated in urine; very high intake can also produce urinary excretion of unchanged nicotinic acid or nicotinamide.

Nutrient-level summary from NIH. Absorption and disposition describe general oral nutritional physiology, not a pharmacokinetic or bioequivalence study of this finished product.

Source: NIH Office of Dietary Supplements: Niacin and nicotinamide

Reference accessed .

Nutrient reference

Biotin

Reference for: Biotin. Source presentation: oral nutrient reference. Source route: oral.

Biological role

Biotin is a cofactor for five carboxylases involved in fatty-acid, glucose and amino-acid metabolism. It also participates in gene regulation and cell signaling; this biochemical role does not itself prove cosmetic benefits from supplementation.

Absorption and disposition

Digestive enzymes release biotin from food proteins, with biotinidase producing free biotin for absorption in the small intestine. Most stored biotin is in the liver. The NIH review reports high absorption of free oral biotin; it does not establish measured pharmacokinetics for this finished combination.

Nutrient-level summary from NIH. Absorption and disposition describe general oral nutritional physiology, not a pharmacokinetic or bioequivalence study of this finished product.

Source: NIH Office of Dietary Supplements: Biotin

Reference accessed .

Nutrient reference

Selenium

Reference for: Selenium. Source presentation: oral nutrient reference. Source route: oral.

Biological role

Selenium is incorporated into selenoproteins including glutathione peroxidases and thioredoxin reductases. These proteins contribute to thyroid-hormone metabolism and protection against oxidative damage.

Absorption and disposition

Absorbed organic and inorganic selenium is metabolized toward an intermediate used to synthesize selenocysteine. A substantial body pool is in skeletal muscle. Urinary excretion is the main mechanism maintaining balance; excretion through feces and lungs also increases at high intake. This general physiology does not establish equal bioavailability among selenium compounds.

Nutrient-level summary from NIH. Absorption and disposition describe general oral nutritional physiology, not a pharmacokinetic or bioequivalence study of this finished product.

Source: NIH Office of Dietary Supplements: Selenium

Reference accessed .

Nutrient reference

Manganese

Reference for: Manganese. Source presentation: oral nutrient reference. Source route: oral.

Biological role

Manganese is a cofactor for enzymes including manganese superoxide dismutase, arginase and pyruvate carboxylase. These functions connect manganese to nutrient metabolism, antioxidant defense and bone formation.

Absorption and disposition

Manganese is absorbed in the small intestine by active transport, with possible diffusion at high intakes. After absorption, most circulating manganese binds to transferrin, albumin or alpha-2-macroglobulin. The cited nutrient review does not establish a plasma half-life or bioavailability for this finished product.

Nutrient-level summary from NIH. Absorption and disposition describe general oral nutritional physiology, not a pharmacokinetic or bioequivalence study of this finished product.

Source: NIH Office of Dietary Supplements: Manganese

Reference accessed .

Nutrient reference

Iodine

Reference for: Iodine. Source presentation: oral nutrient reference. Source route: oral.

Biological role

Iodine is a constituent of the thyroid hormones T4 and T3. These hormones regulate metabolic activity and are important for normal skeletal and nervous-system development.

Absorption and disposition

Iodide is rapidly and almost completely absorbed from the stomach and duodenum. Ingested iodate is reduced to iodide before absorption. The thyroid concentrates circulating iodide for hormone synthesis, and most of the remainder is eliminated in urine. This oral nutrient reference does not characterize topical povidone-iodine or radiopharmaceuticals.

Nutrient-level summary from NIH. Absorption and disposition describe general oral nutritional physiology, not a pharmacokinetic or bioequivalence study of this finished product.

Source: NIH Office of Dietary Supplements: Iodine

Reference accessed .

Nutrient reference

Chromium

Reference for: Chromium. Source presentation: oral nutrient reference. Source route: oral.

Biological role

Chromium has been investigated for possible effects on insulin action and glucose metabolism. The NIH review describes inconsistent clinical findings, so a definite glucose-lowering mechanism or benefit should not be assumed for a chromium supplement.

Absorption and disposition

Absorption of dietary chromium is low, estimated at approximately 0.4–2.5%. The NIH review gives illustrative absorption estimates of about 1.2% for chromium picolinate and 0.4% for chromium chloride, with dietary factors affecting uptake. These reference estimates do not establish bioavailability of this finished product.

Nutrient-level summary from NIH. Absorption and disposition describe general oral nutritional physiology, not a pharmacokinetic or bioequivalence study of this finished product.

Source: NIH Office of Dietary Supplements: Chromium

Reference accessed .

Editorial development perspective

What deserves attention in this formulation.

These notes use the catalogue composition and presentation to frame a technical discussion. They are planning considerations, not tested properties or clinical findings for this product.

The clinical references on this page cover only their named ingredients. These development notes do not resolve the remaining clinical-reference gaps.

About these development notes and source limitations ↗

Balance tablet performance and processability

Listed presentation: Tablets.

Use early development batches to compare blend flow, compression behaviour, tablet strength and the appropriate release test. A harder tablet or a faster disintegration result is not, by itself, a complete product specification. Set priorities around the intended presentation, then check that the chosen process can reproduce them at the proposed scale.

Carry the exact ingredient form into development

Catalogue wording: “Hcl”.

Use the named ingredient form when requesting material specifications and comparing possible suppliers. Resolve assay, water-content and strength-equivalence conventions before converting a formula into batch quantities. A similarly named salt or hydrate should be assessed as a distinct material choice rather than introduced through a naming shortcut.

Translate the listed strength into a quantitative formula

Strength expressions in this entry include “38 mg”, “10 mcg”, “200 IU”, “1 mcg”, “10 mg”, with further amounts in the full composition.

Tie every stated ingredient amount to its intended dosage unit or measure, then distinguish that declared amount from the quantity of raw material needed for a batch. Record any assay or equivalence calculation in the formula. This gives development, purchasing and artwork teams the same strength definition without assigning a patient dose from the catalogue.

Suggested starting point

A practical starting point is to carry the exact ingredient form into development. For this tablets brief, agree the target characteristics and a short set of measurable development questions before comparing prototypes or supplier proposals. Keep unresolved clinical claims outside the product specification until supporting evidence is available.

Discuss this product brief

Manufacturing & packaging brief

Plan the tablet presentation.

Use this preparation guide for B-Carotene 38 mg, Biotin 10 mcg, Cholecalciferol 200 IU, Chromium 10 mcg, Cyanocobalamin 1 mcg, Inositol 10 mg, Iodine 50 mcg, Lysine Hcl 30 mg, Manganese 0.8 mg, Molybdenum 8 mcg, Niacinamide 15 mg, Pyridoxine 1 mg, Selenium 10 mcg, Zinc 3 mg Tablets. These are the decisions to resolve with the technical team before a site, process and commercial scope are confirmed.

Presentation & formulation

Define release type, coating, scoring and any reference-product requirements. Keep each strength and presentation as a separate item in the brief.

Quality & technical transfer

Agree the product specification, analytical methods and applicable dissolution or disintegration requirements. Identify the formula and process information available for transfer.

Review the technical documents

Packaging configuration

Compare the proposed blister, strip or bottle with the formulation and its protection requirements. Specify tablets per primary pack and primary packs per carton.

Explore packaging options

Details to confirm for this record

Full composition
Keep all named components and their individual amounts together in the specification. Ingredient substitutions, omissions and changed ratios require a separate formula and permission review.
Salt and strength wording
Confirm whether the stated amount refers to the named salt, hydrate or equivalent active moiety. Use the agreed expression consistently in the specification, quotation and artwork.

Quantities, MOQ & lead time

For B-Carotene 38 mg, Biotin 10 mcg, Cholecalciferol 200 IU, Chromium 10 mcg, Cyanocobalamin 1 mcg, Inositol 10 mg, Iodine 50 mcg, Lysine Hcl 30 mg, Manganese 0.8 mg, Molybdenum 8 mcg, Niacinamide 15 mg, Pyridoxine 1 mg, Selenium 10 mcg, Zinc 3 mg Tablets (WH-2920), state the tablet count and finished-pack count, target market and reorder forecast. MOQ and lead time depend on the assessed formula, process, components, testing and project readiness; request those terms in writing.

Discuss this manufacturing brief

Explore the context

Build the right manufacturing brief.

Common questions

Before you request a quotation.

B-Carotene 38 mg, Biotin 10 mcg, Cholecalciferol 200 IU, Chromium 10 mcg, Cyanocobalamin 1 mcg, Inositol 10 mg, Iodine 50 mcg, Lysine Hcl 30 mg, Manganese 0.8 mg, Molybdenum 8 mcg, Niacinamide 15 mg, Pyridoxine 1 mg, Selenium 10 mcg, Zinc 3 mg Tablets

What is listed in the catalogue?

The catalogue lists B-Carotene 38 mg, Biotin 10 mcg, Cholecalciferol 200 IU, Chromium 10 mcg, Cyanocobalamin 1 mcg, Inositol 10 mg, Iodine 50 mcg, Lysine Hcl 30 mg, Manganese 0.8 mg, Molybdenum 8 mcg, Niacinamide 15 mg, Pyridoxine 1 mg, Selenium 10 mcg, Zinc 3 mg as tablets in its nutrition & supportive care navigation area and non-beta-lactam manufacturing stream.

How do you confirm manufacturing availability?

Send Walter your requirement for B-Carotene 38 mg, Biotin 10 mcg, Cholecalciferol 200 IU, Chromium 10 mcg, Cyanocobalamin 1 mcg, Inositol 10 mg, Iodine 50 mcg, Lysine Hcl 30 mg, Manganese 0.8 mg, Molybdenum 8 mcg, Niacinamide 15 mg, Pyridoxine 1 mg, Selenium 10 mcg, Zinc 3 mg Tablets. The team reviews the applicable product permission and unit, formulation and equipment fit, testing, packaging and production schedule before confirming the manufacturing scope in writing. Request the relevant product and facility documents with your enquiry.

What do I need for a quotation?

Share the exact composition and strength, tablets presentation, target market, initial quantity, preferred pack and timing. Identify whether this is a new product, development brief or transfer.

The quotation must confirm MOQ, inclusions, prerequisites and lead time for the proposed product and site.

What is needed for Indian and export markets?

For India, share the intended brand or institutional supply requirement, pack sizes, initial order quantity and artwork needs for B-Carotene 38 mg, Biotin 10 mcg, Cholecalciferol 200 IU, Chromium 10 mcg, Cyanocobalamin 1 mcg, Inositol 10 mg, Iodine 50 mcg, Lysine Hcl 30 mg, Manganese 0.8 mg, Molybdenum 8 mcg, Niacinamide 15 mg, Pyridoxine 1 mg, Selenium 10 mcg, Zinc 3 mg Tablets. Confirm the applicable product permission, manufacturing unit and labelling requirements with the team.

For export, identify each destination country, proposed pack, language and registration or dossier requirements. Ask which product-specific quality and stability documents are available. Container compatibility and destination-market requirements need review; a catalogue record does not establish export registration or a shelf-life commitment.

How do I submit my enquiry?

Use the product-specific enquiry button to carry this composition and dosage form into the form. After a successful submission, a receipt reference confirms that your brief has been saved for review. Use the RFQ checklist to prepare the remaining details.

Technical document review

Which documents can I ask Walter to review?

Ask about manufacturing and packing records, specifications, analytical methods, Certificates of Analysis (COA), stability evidence, the Process Validation Protocol (PVP) and Process Validation Report (PVR). The wider checklist below covers supplier qualification, technical transfer and ongoing supply.

View the full document checklist 14 review areas
Site, licence and audit scope
Manufacturing licence, applicable product permissions, GMP certificates, Site Master File, supplier-qualification questionnaire and relevant audit responses.
Manufacturing, packing and batch release
Master Formula Record (MFR), master packing instructions, Batch Manufacturing Record (BMR), Batch Packing Record (BPR), reconciliation and authorised release records.
Process validation and continued verification
Process Validation Protocol (PVP), Process Validation Report (PVR), process performance qualification documents and continued process verification trends.
Equipment, facilities and utilities
Validation Master Plan (VMP), user requirements, DQ/IQ/OQ/PQ records, calibration and maintenance evidence for relevant equipment and utilities.
Cleaning, carryover and hold times
Cleaning Validation Protocol (CVP), Cleaning Validation Report (CVR), residue limits, recovery studies and applicable clean, dirty and process hold-time studies.
Specifications and analytical evidence
Specifications, Method of Analysis (MOA), Standard Testing Procedure (STP), Certificates of Analysis (COA), analytical validation, verification and method-transfer records.
Stability, packaging and transport
Stability protocols/reports, ongoing stability commitments, pack specifications, approved artwork, compatibility and applicable packaging or transport studies.
Development and technology transfer
Development report, technology-transfer protocol/report, gap assessment, control strategy, critical quality attributes and critical process parameters.
Quality reviews, investigations and changes
Product Quality Review (PQR) / Annual Product Review (APR), deviations, CAPA, change control, OOS/OOT trends, complaints, recalls and relevant SOP/training records.
Material suppliers and impurity risks
API/excipient supplier qualification, traceability, material COAs, relevant origin declarations and impurity risk assessments with supporting tests.
Sterile-product evidence, where applicable
Contamination Control Strategy (CCS), media-fill/aseptic simulation reports, sterilisation and filtration validation, environmental monitoring, sterility/endotoxin and container-closure integrity evidence.
Computerised systems and data integrity
Computerised-system validation, access controls, audit-trail review, backup/restore checks and relevant data-integrity procedures.
Market-specific regulatory support
Applicable dossier sections, API master-file/CEP support, bioequivalence or biowaiver evidence and Certificate of a Pharmaceutical Product (CPP/CoPP), where required and available.
Quality agreement and access arrangements
Quality/technical agreement covering responsibilities, release, changes, subcontracting, investigations, complaints, recalls, audits and document access.

Agree the list for the exact product, site, process, pack, market and project stage. QA confirms what exists, applies and may be shared; some records may require an NDA, redaction or controlled review. See document definitions and review guidance.

Important qualification

This B2B catalogue record is not proof of current approval or confirmation that B-Carotene 38 mg, Biotin 10 mcg, Cholecalciferol 200 IU, Chromium 10 mcg, Cyanocobalamin 1 mcg, Inositol 10 mg, Iodine 50 mcg, Lysine Hcl 30 mg, Manganese 0.8 mg, Molybdenum 8 mcg, Niacinamide 15 mg, Pyridoxine 1 mg, Selenium 10 mcg, Zinc 3 mg Tablets is available for sale. It is not prescribing information or patient advice. Any Drugs Rules status, current approval, exemption, applicable unit, licence scope, formulation, claims, brand use, destination-market registration and commercial feasibility require documentary verification and Walter's written confirmation. Read the full regulatory disclaimer.

Composition and classification are taken from Walter's product catalogue. The manufacturing guide helps buyers prepare a technical brief. Clinical references, where shown, describe the cited product and study. Manufacturing guide updated .